(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Aldeyra Therapeutics's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast ALDX's revenue for 2025 to be $1,481,517,369, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $9,150,847,935. On average, 8 Wall Street analysts forecast ALDX's revenue for 2026 to be $2,421,937,996, with the lowest ALDX revenue forecast at $939,162,820, and the highest ALDX revenue forecast at $5,150,721,090.
In 2027, ALDX is forecast to generate $3,873,687,258 in revenue, with the lowest revenue forecast at $2,353,776,817 and the highest revenue forecast at $6,239,922,358.